Mid-Sized Pharmas Mostly Seeing Valuations Rise During Pandemic

22 Apr 2020

Six of seven mid-sized companies enjoyed valuation increases over the first quarter, with four firms up by 7.5% or more. Some are benefiting from direct involvement in addressing the COVID-19 pandemic.

Conceptual image of increasing value of money shown by a coin from small to large number — Valuations rose for many mid-sized biopharmas during Q1 despite the ongoing pandemic

The novel coronavirus pandemic is bringing pressure across the breadth of the biopharmaceutical industry, from big pharmas to biotech. Square in the middle are mid-size firms, a tier that includes big biotechs and specialty companies, which face unique pressures due to smaller and less diversified product portfolios than larger firms.

However, for several mid-sized firms, the pandemic also is providing opportunity, and all but one of the companies reviewed by...